Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CCXI NASDAQ:EIDX NASDAQ:FGEN NASDAQ:HCM NASDAQ:IMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCXIChemoCentryx$51.99$51.95$14.95▼$52.00$3.71B1.221.68 million shs113 shsEIDXEidos Therapeutics$122.21$123.21$28.39▼$132.54$4.75B-0.16128,113 shsN/AFGENFibroGen$7.15-2.7%$6.97$4.50▼$38.25$29.71M0.7476,113 shs59,782 shsHCMHUTCHMED$16.04+0.4%$14.92$11.51▼$21.50$2.78B0.5296,560 shs28,642 shsIMABI-Mab$2.13+3.9%$1.78$0.60▼$3.08$167.40M1.4394,850 shs224,260 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCXIChemoCentryx0.00%0.00%0.00%0.00%0.00%EIDXEidos Therapeutics0.00%0.00%0.00%0.00%0.00%FGENFibroGen+18.74%+29.17%-4.92%+6.06%-67.46%HCMHUTCHMED-2.02%+0.48%-5.17%+16.40%-4.08%IMABI-Mab-11.26%-8.07%-22.35%+207.81%+35.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCCXIChemoCentryxN/AN/AN/AN/AN/AN/AN/AN/AEIDXEidos TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AFGENFibroGen4.7253 of 5 stars3.34.00.04.73.83.30.6HCMHUTCHMED1.6886 of 5 stars2.03.00.00.02.50.01.9IMABI-Mab2.9694 of 5 stars3.73.00.00.02.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCXIChemoCentryx 0.00N/AN/AN/AEIDXEidos Therapeutics 0.00N/AN/AN/AFGENFibroGen 2.50Moderate Buy$250.003,396.50% UpsideHCMHUTCHMED 2.00Hold$19.0018.45% UpsideIMABI-Mab 3.33Buy$6.00181.69% UpsideCurrent Analyst Ratings BreakdownLatest FGEN, IMAB, CCXI, EIDX, and HCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.007/9/2025IMABI-MabHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.006/27/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.005/13/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$250.00 ➝ $250.005/13/2025HCMHUTCHMEDHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCXIChemoCentryx$32.22M115.14N/AN/A$4.09 per share12.71EIDXEidos Therapeutics$26.69M177.99N/AN/A$4.57 per share26.74FGENFibroGen$29.62M0.98N/AN/A($50.89) per share-0.14HCMHUTCHMED$630.20M4.44$0.29 per share55.60$4.43 per share3.62IMABI-Mab$3.89M44.71N/AN/A$2.47 per share0.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCXIChemoCentryx-$131.76M-$1.89N/AN/AN/A-357.01%-48.52%-30.59%N/AEIDXEidos Therapeutics-$37.83M-$1.03N/AN/AN/AN/A-65.21%-53.04%N/AFGENFibroGen-$47.58M-$2.50N/AN/AN/A-9.73%N/A-24.77%8/5/2025 (Estimated)HCMHUTCHMED$37.73MN/A0.0010.99N/AN/AN/AN/A8/7/2025 (Estimated)IMABI-Mab-$22.23MN/A0.00N/AN/AN/A-19.81%-18.63%8/27/2025 (Estimated)Latest FGEN, IMAB, CCXI, EIDX, and HCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025FGENFibroGen-$0.09N/AN/AN/A$2.88 millionN/A5/12/2025Q1 2025FGENFibroGen$0.75-$4.00-$4.75$0.05$2.00 million$2.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCCXIChemoCentryxN/AN/AN/AN/AN/AEIDXEidos TherapeuticsN/AN/AN/AN/AN/AFGENFibroGenN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/AIMABI-MabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCXIChemoCentryx0.024.544.47EIDXEidos Therapeutics0.1411.1011.10FGENFibroGenN/A2.021.98HCMHUTCHMED0.082.832.70IMABI-MabN/A22.3522.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCXIChemoCentryx81.09%EIDXEidos Therapeutics31.40%FGENFibroGen72.71%HCMHUTCHMED8.82%IMABI-Mab38.38%Insider OwnershipCompanyInsider OwnershipCCXIChemoCentryx8.30%EIDXEidos Therapeutics70.10%FGENFibroGen3.07%HCMHUTCHMED3.60%IMABI-Mab22.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCXIChemoCentryx17871.36 million65.43 millionOptionableEIDXEidos Therapeutics7038.87 millionN/ANot OptionableFGENFibroGen5704.04 million3.92 millionOptionableHCMHUTCHMED1,811174.32 million168.05 millionNot OptionableIMABI-Mab38081.66 million63.61 millionOptionableFGEN, IMAB, CCXI, EIDX, and HCM HeadlinesRecent News About These CompaniesI-Mab Presents Promising Phase 1b Givastomig Combination Data for Gastric Cancers at ESMO GI 2025July 9 at 8:05 PM | msn.comI-Mab (NASDAQ:IMAB) Given Buy Rating at HC WainwrightJuly 9 at 9:03 AM | marketbeat.comNeedham & Company LLC Reiterates Buy Rating for I-Mab (NASDAQ:IMAB)July 9 at 9:03 AM | marketbeat.comI-Mab Reports Encouraging Phase 1b Data for Givastomig in Combination with Nivolumab and mFOLFOX6 at ESMO GI 2025, Confirming 83% Objective Response Rate in Gastric ... - NasdaqJuly 4, 2025 | nasdaq.comI-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025July 2, 2025 | globenewswire.comI-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research - MorningstarJuly 2, 2025 | morningstar.comMI-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer ResearchJune 30, 2025 | globenewswire.comI-Mab (NASDAQ:IMAB) Price Target Raised to $5.00June 27, 2025 | marketbeat.comI-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025June 26, 2025 | globenewswire.comI-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025June 18, 2025 | manilatimes.netMI-Mab Biopharma: I-Mab Regains Compliance with Nasdaq Minimum Bid Price RequirementJune 13, 2025 | finanznachrichten.deI-Mab regains compliance with Nasdaq’s listing ruleJune 12, 2025 | kalkinemedia.comKI-Mab Regains Compliance with Nasdaq Minimum Bid Price RequirementJune 12, 2025 | manilatimes.netMI-Mab Regains Nasdaq Compliance with Minimum Bid PriceJune 12, 2025 | tipranks.comI-Mab regains Nasdaq compliance as shares maintain $1 minimum bidJune 12, 2025 | investing.comI-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden CrossJune 11, 2025 | zacks.comI-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy?June 6, 2025 | zacks.comI-Mab to Participate in the H.C. Wainwright “HCW@Home” SeriesJune 3, 2025 | finance.yahoo.comI-Mab Advances Givastomig in Gastric Cancer with Promising Clinical DataJune 2, 2025 | tipranks.comI-Mab stock surges on Lucid Capital’s buy rating initiationMay 29, 2025 | za.investing.comI-Mab stock surges on Lucid Capital's buy rating initiationMay 28, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFGEN, IMAB, CCXI, EIDX, and HCM Company DescriptionsChemoCentryx NASDAQ:CCXIChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.Eidos Therapeutics NASDAQ:EIDXEidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.FibroGen NASDAQ:FGEN$7.15 -0.20 (-2.72%) Closing price 04:00 PM EasternExtended Trading$7.30 +0.15 (+2.10%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.HUTCHMED NASDAQ:HCM$16.04 +0.07 (+0.44%) Closing price 04:00 PM EasternExtended Trading$16.05 +0.01 (+0.06%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.I-Mab NASDAQ:IMAB$2.13 +0.08 (+3.90%) Closing price 04:00 PM EasternExtended Trading$2.10 -0.03 (-1.41%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
